{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T17:42:03Z","timestamp":1765993323907,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>In the tyrosine kinase inhibitor era, the blast phase of chronic myeloid leukaemia (BP-CML) renders an uncommon presentation and has a poor prognosis with an estimated overall survival below 20%. Mixed-phenotype blast phase is even more infrequent, presenting in 3.3% of these patients. Blast phase manifests along haematological sarcomas, with extramedullary activity in lymph nodes, skin and bone. We report the case of a patient with an ovarian sarcoma as an extramedullary presentation of mixed-phenotype BP-CML refractory to conventional treatment which responded to immunotherapy against CD33 and CD19.<\/jats:p>","DOI":"10.1136\/bcr-2021-243745","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T07:16:48Z","timestamp":1636615008000},"page":"e243745","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia"],"prefix":"10.1136","volume":"14","author":[{"given":"Roberto","family":"Ovilla-Martinez","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alejandro","family":"Weber S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico"},{"name":"Surgery Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X\u00f3chitl","family":"Cota-Rangel","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-9437","authenticated-orcid":false,"given":"Pamela Elena","family":"Baez-Islas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2025082801320044000_14.11.e243745.1","unstructured":"World Health Organization classification of tumours . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In: Swerdlow SH , Campo E , Harris NL , eds. 4th edn. Lyon, 2017."},{"key":"2025082801320044000_14.11.e243745.2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/17474086.2017.1330144","article-title":"Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?","volume":"10","author":"Patel","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2025082801320044000_14.11.e243745.3","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"2025082801320044000_14.11.e243745.4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.12659\/AJCR.899621","article-title":"Bilineal extramedullary blast crisis as an initial presentation of chronic myeloid leukemia: a case report and literature review","volume":"17","author":"Gao","year":"2016","journal-title":"Am J Case Rep"},{"key":"2025082801320044000_14.11.e243745.5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy"},{"key":"2025082801320044000_14.11.e243745.6","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00277-020-04221-0","article-title":"Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies","volume":"99","author":"Viardot","year":"2020","journal-title":"Ann Hematol"},{"key":"2025082801320044000_14.11.e243745.7","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1478725"},{"key":"2025082801320044000_14.11.e243745.8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637951","article-title":"Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia","volume":"11","author":"Brethon","year":"2021","journal-title":"Front Oncol"},{"key":"2025082801320044000_14.11.e243745.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373902"},{"key":"2025082801320044000_14.11.e243745.10","doi-asserted-by":"crossref","first-page":"NA","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"key":"2025082801320044000_14.11.e243745.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-687830"},{"key":"2025082801320044000_14.11.e243745.12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111602","article-title":"Runx1 mutations identify an entity of blast phase chronic myeloid leukemia (BP-CML) patients with distinct phenotype, transcriptional profile and drug vulnerabilities","volume":"132","author":"Awad","year":"2018","journal-title":"Blood"},{"key":"2025082801320044000_14.11.e243745.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-370981"},{"key":"2025082801320044000_14.11.e243745.14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12288-014-0471-4","article-title":"Chronic myeloid leukemia with extramedullary blast crisis: two unusual sites with review of literature","volume":"32","author":"Sahu","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2025082801320044000_14.11.e243745.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.6442"},{"key":"2025082801320044000_14.11.e243745.16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/PGP.0b013e31825183ad","article-title":"Extramedullary hematopoiesis involving uterus, fallopian tubes, and ovaries, mimicking bilateral tuboovarian abscesses","volume":"31","author":"Palatnik","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"2025082801320044000_14.11.e243745.17","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/ajh.25317","article-title":"Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab","volume":"94","author":"El Chaer","year":"2019","journal-title":"Am J Hematol"},{"key":"2025082801320044000_14.11.e243745.18","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0899"},{"key":"2025082801320044000_14.11.e243745.19","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000219485"},{"key":"2025082801320044000_14.11.e243745.20","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1097\/MPH.0000000000001201","article-title":"Clinical and radiographic response of extramedullary leukemia in patients treated with Gemtuzumab Ozogamicin","volume":"41","author":"McNeil","year":"2019","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:32:09Z","timestamp":1756369929000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,11]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bcr-2021-243745"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243745","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}